What is HC Wainwright’s Estimate for CADL FY2024 Earnings?

Candel Therapeutics, Inc. (NASDAQ:CADL) – Investment analysts at HC Wainwright upped their FY2024 earnings per share estimates for Candel Therapeutics in a note issued to investors on Wednesday, December 18th. HC Wainwright analyst V. Bernardino now anticipates that the company will post earnings per share of ($1.59) for the year, up from their prior forecast of ($1.65). HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Candel Therapeutics’ Q4 2024 earnings at ($0.27) EPS and FY2025 earnings at ($1.35) EPS.

Candel Therapeutics Price Performance

NASDAQ CADL opened at $8.75 on Friday. The stock has a market cap of $284.17 million, a price-to-earnings ratio of -5.06 and a beta of -0.95. Candel Therapeutics has a 52-week low of $1.06 and a 52-week high of $14.60. The business has a 50 day simple moving average of $5.46 and a 200 day simple moving average of $6.05. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.18 and a current ratio of 1.18.

Hedge Funds Weigh In On Candel Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp bought a new stake in Candel Therapeutics in the second quarter valued at approximately $338,000. Geode Capital Management LLC increased its holdings in shares of Candel Therapeutics by 12.8% during the 3rd quarter. Geode Capital Management LLC now owns 448,997 shares of the company’s stock worth $3,112,000 after acquiring an additional 51,111 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in Candel Therapeutics in the 2nd quarter valued at $162,000. Rhumbline Advisers acquired a new stake in Candel Therapeutics during the 2nd quarter valued at $143,000. Finally, Barclays PLC boosted its position in Candel Therapeutics by 327.1% during the third quarter. Barclays PLC now owns 28,688 shares of the company’s stock worth $199,000 after purchasing an additional 21,971 shares during the period. Institutional investors own 13.93% of the company’s stock.

Insiders Place Their Bets

In other Candel Therapeutics news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of Candel Therapeutics stock in a transaction on Friday, October 11th. The shares were sold at an average price of $6.05, for a total value of $90,750.00. Following the sale, the insider now directly owns 944,873 shares in the company, valued at approximately $5,716,481.65. The trade was a 1.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Paul B. Manning bought 1,250,000 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were bought at an average price of $6.00 per share, for a total transaction of $7,500,000.00. Following the acquisition, the director now directly owns 1,303,752 shares of the company’s stock, valued at $7,822,512. This represents a 2,325.49 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 66,127 shares of company stock worth $349,911. Corporate insiders own 41.60% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.